ISIN | LU0432979614 |
---|---|
Valor Number | 10261626 |
Bloomberg Global ID | |
Fund Name | JPM Global Healthcare Fund A acc USD |
Fund Provider |
J.P. Morgan Bank Luxembourg S.A.
6, route de Trèves L-2633, Senningerberg Grand Duchy of Luxembourg |
Fund Provider | J.P. Morgan Bank Luxembourg S.A. |
Representative in Switzerland |
JPMorgan Asset Management (Switzerland) LLC Genève Phone: +41 22 744 11 11 |
Distributor(s) |
JP Morgan Asset Management (Europe) Sàrl Senningerberg Phone: +352 34 10 1 |
Asset Class | Equities |
EFC Category | Equity Health Care |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | To achieve a return by investing primarily in pharmaceutical, biotechnology, healthcare services, medical technology and life sciences companies ("Healthcare Companies"), globally. |
Peculiarities |
Current Price * | 482.10 USD | 31.03.2025 |
---|---|---|
Previous Price * | 485.69 USD | 28.03.2025 |
52 Week High * | 557.48 USD | 03.09.2024 |
52 Week Low * | 463.83 USD | 20.12.2024 |
NAV * | 482.10 USD | 31.03.2025 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 4,060,160,877 | |
Unit/Share Assets *** | 1,046,757,413 | |
Trading Information SIX |
YTD Performance | +3.01% |
31.12.2024 - 31.03.2025
31.12.2024 31.03.2025 |
---|---|---|
YTD Performance (in CHF) | -0.12% |
31.12.2024 - 31.03.2025
31.12.2024 31.03.2025 |
1 month | -3.14% |
28.02.2025 - 31.03.2025
28.02.2025 31.03.2025 |
3 months | +3.01% |
31.12.2024 - 31.03.2025
31.12.2024 31.03.2025 |
6 months | -9.21% |
30.09.2024 - 31.03.2025
30.09.2024 31.03.2025 |
1 year | -4.17% |
02.04.2024 - 31.03.2025
02.04.2024 31.03.2025 |
2 years | +4.12% |
31.03.2023 - 31.03.2025
31.03.2023 31.03.2025 |
3 years | -4.25% |
31.03.2022 - 31.03.2025
31.03.2022 31.03.2025 |
5 years | +43.44% |
31.03.2020 - 31.03.2025
31.03.2020 31.03.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Eli Lilly and Co | 10.18% | |
---|---|---|
UnitedHealth Group Inc | 7.09% | |
AbbVie Inc | 6.69% | |
Johnson & Johnson | 6.25% | |
AstraZeneca PLC | 5.08% | |
Boston Scientific Corp | 4.23% | |
Thermo Fisher Scientific Inc | 3.87% | |
Sanofi SA | 3.53% | |
Bristol-Myers Squibb Co | 3.37% | |
Stryker Corp | 3.35% | |
Last data update | 28.02.2025 |
TER *** | 1.69% |
---|---|
TER date *** | 31.12.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 1.50% |
Ongoing Charges *** | 1.69% |
SRRI ***
|
|
SRRI date *** | 28.02.2025 |